Iovance Biotherapeutics, Inc. (LON:0JDK)
5.77
+0.19 (3.45%)
At close: Feb 21, 2025
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $58.56M USD in the quarter ending September 30, 2024, with 12,385.07% growth. This brings the company's revenue in the last twelve months to $90.86M, up 12,751.20% year-over-year. In the year 2023, Iovance Biotherapeutics had annual revenue of $1.19M.
Revenue (ttm)
$90.86M
Revenue Growth
+12,751.20%
P/S Ratio
n/a
Revenue / Employee
$163.12K
Employees
557
Market Cap
1.39B GBP
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Iovance Biotherapeutics News
- 7 hours ago - Iovance Biotherapeutics Inc (IOVA) Announces Inducement Stock Options for New Employees - GuruFocus
- 4 days ago - Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025 - GlobeNewsWire
- 8 days ago - PERCEPTIVE ADVISORS LLC Reduces Stake in Iovance Biotherapeutics Inc - GuruFocus
- 10 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 12 days ago - Iovance Biotherapeutics Shares Fell Today: What's Going On? - Benzinga
- 13 days ago - Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer - GlobeNewsWire
- 24 days ago - What's Wrong With Iovance Biotherapeutics Stock? - The Motley Fool
- 25 days ago - Where Will Iovance Biotherapeutics Be in 5 Years? - The Motley Fool